Drug · DIN 02498537
ADYNOVATE
125 UNITS/ML. KIT CONTAINING: A) SINGLE-USE VIAL AND B) DILUENT (2 ML)
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 16, 2021; first marketed July 16, 2021.
- Drug Identification Number (DIN)
- 02498537
- Company (DIN owner)
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Kit; Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Coagulation factor viii B02BD02
- Class
- Human
- Record last updated
- September 21, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED | 250 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 15, 2021: NOC 25021New Drug Submission (NDS) · Transfer of drug identification number (din). labelling updates
- May 1, 2020: NOC 23546Supplement to a New Drug Submission (SNDS) · New strengths
Other DINs named ADYNOVATE
- DIN 02459078 · Marketed
- DIN 02498545 · Marketed
- DIN 02498588 · Marketed
- DIN 02498596 · Marketed
- DIN 02498626 · Marketed
- DIN 02459035 · Dormant
- DIN 02459043 · Dormant
- DIN 02459051 · Dormant
- DIN 02498553 · Approved
- DIN 02498561 · Approved
- DIN 02498618 · Approved